search
Back to results

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

Primary Purpose

Postoperative Pain

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Q8003
Morphine sulfate
Oxycodone HCl
Q8003
Morphine sulfate
Oxycodone HCl 4mg
Sponsored by
QRxPharma Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Postoperative Pain focused on measuring Bunionectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is male or female and at least 18 years of age.
  • Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control, or be surgically sterile or postmenopausal (amenorrhea for ≥ 12 months). Non-pregnancy will be confirmed by pregnancy tests conducted at Screening and Pre-treatment.
  • Patient is scheduled for bunionectomy surgery, meets the criteria of an ASA Class I to III, and is willing to stay in the study center for at least 48 hours from the initial dose of study medication post surgery.
  • To be randomized after surgery, the patient must report moderate to severe pain (a score of 2 or more on the 4 point Likert scale or at least 4 on the 11 point NPRS scale).

Exclusion Criteria:

  • In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
  • Used opiates continuously (including tramadol) for more than ten days in the past year.
  • Hypersensitivity or poor tolerance to ibuprofen or short term opioids.
  • Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery).
  • Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
  • Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
  • Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).

Sites / Locations

  • Associated Foot and Ankle Specialists
  • Advanced Clinical Research Institute
  • Crossroads Research, Inc.
  • Chesapeake Foot and Ankle
  • Advanced Regional Center for Ankle and Foot Care
  • Jean Brown Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Active Comparator

Active Comparator

Experimental

Active Comparator

Active Comparator

Arm Label

Q8003 12mg/8mg

Morphine sulfate 12 mg

Oxycodone HCl 8mg

Q8003 6mg/4mg

Morphine sulfate 6mg

Oxycodone HCl 4mg

Arm Description

Combination

Single component

Single component

Combination

Single component

Single component

Outcomes

Primary Outcome Measures

Difference in pain intensity scores from baseline

Secondary Outcome Measures

Safety: adverse events

Full Information

First Posted
January 27, 2009
Last Updated
May 15, 2012
Sponsor
QRxPharma Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00831051
Brief Title
Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients
Official Title
A Double-Blind, Randomized, Multi-Center, Repeat-Dose, Comparison of the Analgesic Efficacy and Safety of the Opioid Combination Q8003 to Each of the Individual Milligram Components (Oxycodone and Morphine) in the Management of Acute Moderate to Severe Pain Following Bunionectomy Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
December 2008 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
February 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
QRxPharma Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a randomized, double-blind, multicenter, fixed dose factorial study of Q8003 12 mg/8 mg and Q8003 6 mg/4 mg versus its individual morphine sulfate and oxycodone hydrochloride components for the management of acute moderate to severe postoperative pain following bunionectomy surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Bunionectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
197 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Q8003 12mg/8mg
Arm Type
Experimental
Arm Description
Combination
Arm Title
Morphine sulfate 12 mg
Arm Type
Active Comparator
Arm Description
Single component
Arm Title
Oxycodone HCl 8mg
Arm Type
Active Comparator
Arm Description
Single component
Arm Title
Q8003 6mg/4mg
Arm Type
Experimental
Arm Description
Combination
Arm Title
Morphine sulfate 6mg
Arm Type
Active Comparator
Arm Description
Single component
Arm Title
Oxycodone HCl 4mg
Arm Type
Active Comparator
Arm Description
Single component
Intervention Type
Drug
Intervention Name(s)
Q8003
Intervention Description
One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
Intervention Type
Drug
Intervention Name(s)
Morphine sulfate
Intervention Description
One morphine sulfate 12mg IR capsule q6h
Intervention Type
Drug
Intervention Name(s)
Oxycodone HCl
Intervention Description
One oxycodone HCl 8mg IR Capsule q6h
Intervention Type
Drug
Intervention Name(s)
Q8003
Intervention Description
One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
Intervention Type
Drug
Intervention Name(s)
Morphine sulfate
Intervention Description
Two morphine sulfate 3mg IR capsules q6h
Intervention Type
Drug
Intervention Name(s)
Oxycodone HCl 4mg
Intervention Description
Two oxycodone HCl 2mg IR Capsules q6h
Primary Outcome Measure Information:
Title
Difference in pain intensity scores from baseline
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
Safety: adverse events
Time Frame
48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is male or female and at least 18 years of age. Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control, or be surgically sterile or postmenopausal (amenorrhea for ≥ 12 months). Non-pregnancy will be confirmed by pregnancy tests conducted at Screening and Pre-treatment. Patient is scheduled for bunionectomy surgery, meets the criteria of an ASA Class I to III, and is willing to stay in the study center for at least 48 hours from the initial dose of study medication post surgery. To be randomized after surgery, the patient must report moderate to severe pain (a score of 2 or more on the 4 point Likert scale or at least 4 on the 11 point NPRS scale). Exclusion Criteria: In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that, in the opinion of the Investigator, would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments. Used opiates continuously (including tramadol) for more than ten days in the past year. Hypersensitivity or poor tolerance to ibuprofen or short term opioids. Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery). Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003. Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia). Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patricia T. Richards, MD, Ph.D.
Organizational Affiliation
QRxPharma Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Associated Foot and Ankle Specialists
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85050
Country
United States
Facility Name
Advanced Clinical Research Institute
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
Crossroads Research, Inc.
City
Owings Mills
State/Province
Maryland
ZIP/Postal Code
21117
Country
United States
Facility Name
Chesapeake Foot and Ankle
City
Pasadena
State/Province
Maryland
ZIP/Postal Code
21122
Country
United States
Facility Name
Advanced Regional Center for Ankle and Foot Care
City
Altoona
State/Province
Pennsylvania
ZIP/Postal Code
92801
Country
United States
Facility Name
Jean Brown Research
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

We'll reach out to this number within 24 hrs